Quantcast

Folic Acid Prevents First Heart Attack, but Not Second

February 8, 2011

(Ivanhoe Newswire) — A perplexing medical paradox that taking folic acid, a B vitamin, lowers homocysteine in the blood, which epidemionlogical evidence indicates should lower the risk of heart attack. However, clinical trials of folic acid haven’t shown the expected benefit.

The explanation is surprisingly simple; lowering homocysteine prevents platelets sticking, which stops blood clots, and is the same thing asprin does. If people in the trials were already taking aspirin there would be no extra benefit in lowering homocysteine with folic acid. Aspirin was in fact widely used by participants in the trials because they were mainly conducted in patients who had already had a heart attack or other cardiovascular diseases.

Research led by Dr David Wald at the Wolfson Institute of Preventive Medicine at Barts and The London School of Medicine and Dentistry showed that there was a difference in the reduction in heart disease events between the five trials with the lowest aspirin use (60 per cent of the participants took aspirin) and the five trials with the highest use (91 per cent took aspirin).

The observed risk reduction was six per cent but it would have been 15 per cent if no one had been taking aspirin. Research was based on 75 epidemiological studies involving about 50,000 participants and clinical trials involving about 40,000 participants.

“The explanation has important implications,” Dr David Wald, the lead author of the paper, was quoted as saying. “The negative clinical trial evidence should not close the door on folic acid ““ folic acid may still be of benefit in people who have not had a heart attack because they will generally not be taking aspirin”.

SOURCE: PLOS, published online February 2, 2011




comments powered by Disqus